Dennis Spiller, DO
Cardiovascular Disease · Hollywood, FLNPI 1922047398
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Novartis at 27.0% of the total. Reporting peaked in 2019 at $373 and has fallen 66.9% since, to $123 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 83 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$448
- Pfizer$210
- Merck$185
- Boehringer Ingelheim$166
- Johnson & Johnson$164
- Sanofi-aventis U.S. LLC$81
- plus $407 from 12 others
Across 91 payments — averaging $7752.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$281K
- American Regent$207K
- Novartis$148K
- AbbVie$48K
- Vifor (international) Ltd.$10K
- Janssen Research & Development, LLC$8K
- plus $2K from 1 others
What the payments were for
- Food & beverage$1,64899%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 23 | $448 |
| Pfizer | 10 | $210 |
| Merck | 8 | $185 |
| Boehringer Ingelheim | 7 | $166 |
| Johnson & Johnson | 10 | $164 |
| Sanofi-aventis U.S. LLC | 4 | $81 |
| Amgen | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $56 |
| AstraZeneca | 3 | $55 |
| Lexicon Pharmaceuticals, Inc. | 2 | $49 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $46 |
| Heartflow, Inc. | 1 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $19 |
| G Medical Diagnostic Services, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$1,659 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $68,040 |
| EntrestoSacubitril/Valsartan | 28 | $25,380 |
| XareltoRivaroxaban | 18 | $14,355 |
| Diltiazem 12hr ErDiltiazem Hcl | 13 | $2,336 |
| Labetalol Hcl | 42 | $1,136 |
| Telmisartan | 30 | $630 |
| Chlorthalidone | 22 | $452 |
| Carvedilol | 54 | $387 |
| ClopidogrelClopidogrel Bisulfate | 30 | $286 |
| Metoprolol Succinate | 35 | $263 |
| Atorvastatin Calcium | 41 | $248 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 21 | $219 |
| Amlodipine Besylate | 40 | $214 |
| Rosuvastatin Calcium | 13 | $197 |
| Metoprolol Tartrate | 14 | $86 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $210 | $68,04068 claims |
| NovartisEntresto | $448 | $25,38028 claims |
| Johnson & JohnsonXarelto | $164 | $14,35518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Hollywood
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
- Neel PatelMaitland$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.